HomeQuestion

Do you anticipate added benefit of triple agonist therapy for patients with early type 2 diabetes mellitus and MASLD given evidence of glucagon resistance?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Do you recommend avoiding the use of GLP-1 agonists in patients with a history of suicidal thoughts, given recent evidence showing an association with increased risks of psychiatric disorders, including depression and suicidal behavior?

How would you manage a patient who presents with hair loss that began after they started a GLP-1 inhibitor?

In patients with T1DM, when would you consider the use of amylin analogues for control of post prandial hyperglycemia?

Do you recommend that patients with type 2 diabetes who regularly drink artificially sweetened beverages continue their current consumption, gradually reduce their intake, or switch entirely to water in light of the SODAS trial?

Do you recommend the use of diazoxide for the management of reactive hypoglycemia in patients who have not responded to acarbose or dietary modifications?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.